A Case Report and Literature Review of the Role of Dupilumab in the Management of Lichen Planus: Cause or Treatment?
| Autor: | Gajraj FA; Medicine, Ross University School of Medicine, Miramar, USA., Zahir J; Surgery, Ross University School of Medicine, Miramar, USA., Adereti C; Surgery, Ross University School of Medicine, Miramar, USA., Gajraj MH; Medicine, Coral Springs Medical Group, Coral Springs, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Jul 02; Vol. 15 (7), pp. e41274. Date of Electronic Publication: 2023 Jul 02 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.41274 |
| Abstrakt: | Lichen planus (LP) is a chronic inflammatory skin condition characterized by the six Ps (ie. purple, planar, polygonal, pruritic, plaques, and papules) often causing physical, emotional, and psychological stress for the person affected. Drug-induced LP has been described after the administration of drugs like antihypertensives, non-steroidal anti-inflammatory drugs (NSAIDs), and biologics like adalimumab and etanercept. Currently, there is a dearth of studies discussing the association between LP and dupilumab. Here, we present the case of a young adult female who developed LP 24 months after treatment with dupilumab for severe atopic dermatitis. We also conducted a review of the literature discussing the association between LP and dupilumab. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Gajraj et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|